Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects
- 30 September 1988
- journal article
- case report
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 19 (3) , 509-515
- https://doi.org/10.1016/s0190-9622(88)70206-6
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Plasma 5-S-Cysteinyldopa Correlates With Tumor Size in Melanoma-Bearing MiceJournal of Investigative Dermatology, 1988
- Risk Factors for Cutaneous MelanomaPublished by American Medical Association (AMA) ,1987
- Malignant Melanoma Prognostic Factors 7: Elective Lymph Node DissectionThe Journal of Dermatologic Surgery and Oncology, 1985
- Precursors to Malignant MelanomaPublished by American Medical Association (AMA) ,1984
- Dysplastic Nevus SyndromeHospital Practice, 1984
- An Estimate of the Melanocyte Mass in HumansJournal of Investigative Dermatology, 1983
- The Treatment of Stage I Melanoma of the Extremities with Regional Hyperthermic Isolation PerfusionAnnals of Surgery, 1982
- Origin of Familial Malignant Melanomas From Heritable Melanocytic LesionsArchives of Dermatology, 1978
- 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observationsPublished by Elsevier ,1977
- Selection of the Optimum Surgical Treatment of Stage I Melanoma By Depth of MicroinvasionAnnals of Surgery, 1975